Clinical Trials on Transitional Cell Carcinoma in South Africa

Total 3200 results

Lipac Oncology LLC
TesoRx Pharma, LLC

Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Urologic Neoplasms | Urogenital Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Non-Muscle Invasive Bladder Cancer | Urinary Bladder | Bladder Cancer Cell Transitional

United States
Noah Hahn, M.D.
Pfizer; Hoosier Cancer Research Network

Terminated

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Transitional Cell Carcinoma of the Bladder

United States, United Kingdom
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands

Recruiting

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)

Upper Tract Urothelial Carcinoma

Norway, Spain, Netherlands
Matthew Galsky
Novartis Pharmaceuticals; Hoosier Cancer Research Network

Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Urothelial Carcinoma | Bladder Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Medical Research Council

Completed

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Canada, United Kingdom, Norway, New Zealand, Netherlands, South Africa, Brazil, Finland
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; University of Stellenbosch

Withdrawn

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

HIV Infection | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | FIGO Stage IIB Cervix Carcinoma | FIGO Stage III Cervix Carcinoma | FIGO Stage IVA Cervix Carcinoma

South Africa, Zimbabwe
Seagen Inc.

Recruiting

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Urothelial Carcinoma

United States, France
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer (KEYNOTE143)

Metastatic Urothelial Carcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States, Canada
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms | Metastases, Neoplasm

United States
Genentech, Inc.

Approved for marketing

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Urothelial Carcinoma

United States
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, South Africa
Bayer

Completed

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)

Carcinoma, Transitional Cell

United States, Spain, Hungary, China, Belgium, Korea, Republic of, Taiwan, Australia, Singapore, Canada, Japan, Sweden, Russian Federation, Germany, Italy, Israel, Ireland, France, Austria, Denmark, Portugal, Switzerland, Czechia, Slo... and more
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States, Canada
AstraZeneca

Completed

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma (PREVAIL)

Urothelial Carcinoma

United States
Hoffmann-La Roche

Terminated

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010)

Carcinoma, Transitional Cell

United States, Korea, Republic of, France, United Kingdom, Belgium, Canada, China, Greece, Spain, Turkey, Japan, Czechia, Israel, Italy, Russian Federation, Poland, Switzerland, Australia, Germany, Netherlands, Taiwan, Ukraine, Serbia, Finla...
Bristol-Myers Squibb

Completed

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Transitional Cell Carcinoma | Bladder Cancer | Metastasis

United States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Hoffmann-La Roche

Completed

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

Urothelial Carcinoma

Spain, United States, Korea, Republic of, Canada, United Kingdom, Czechia, Australia, Belgium, Brazil, China, Estonia, Finland, Greece, Hong Kong, Italy, Poland, Portugal, Slovenia, Mexico, Georgia, Russian Federation, Singapore, Th... and more
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

High Grade Upper Tract Urothelial Carcinoma

United States
International Atomic Energy Agency
Tata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaborators

Unknown

Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (HYPNO)

Squamous Cell Carcinoma of the Head and Neck

India, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Australia, Argentina, Chile, Israel, Belgium
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

UC (Urothelial Cancer)

United States, Netherlands, Spain, Denmark, Belgium, Israel, Italy, Germany, France, Japan, United Kingdom
Bio-Thera Solutions

Completed

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China, Mexico, South Africa, Turkey, Ukraine
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Dendreon

Terminated

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Urothelial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, Puerto Rico, South Africa
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
Antiva Biosciences

Completed

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

Cervical Cancer | Human Papilloma Virus | HSIL, High Grade Squamous Intraepithelial Lesions | Cervical Dysplasia | HSIL of Cervix | High-Grade Cervical Intraepithelial Neoplasia | HIV Negative | CIN - Cervical Intraepithelial Neoplasia | Cervical Neoplasm

South Africa
Bristol-Myers Squibb
Pierre Fabre Medicament

Completed

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Kidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, Bladder

United States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
Infinity Pharmaceuticals, Inc.
Bristol-Myers Squibb

Completed

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Solid Tumor | Bladder Cancer | Advanced Cancer | Urothelial Carcinoma

France, Spain, United States, Italy, Czechia, Poland, Serbia
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Steba Biotech S.A.
PrimeVigilance; ICON plc

Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (UCM301)

Transitional Cell Cancer of Renal Pelvis and Ureter

United States, Israel, Spain, Italy, France, Germany, Austria
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
European Organisation for Research and Treatment...

Completed

Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer

Lung Cancer

Italy, South Africa, United Kingdom, Netherlands, Poland
Pfizer

Completed

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung (NSCLC)

Ukraine, Poland, Romania, South Africa
Medical University of South Carolina

Terminated

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Bladder Cancer

United States
Astellas Pharma Global Development, Inc.
Seagen Inc.

Recruiting

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBC

United States, Canada, France, Spain, United Kingdom, Germany
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States

Clinical Trials on Transitional Cell Carcinoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations